敏芯股份(688286.SH):以396.4萬元收購關聯人朱瀟挺所持芯儀微20%少數股東權益
格隆匯11月9日丨敏芯股份(688286.SH)公佈,公司於2021年9月29日召開第二屆董事會第二十次會議審議通過了《關於收購控股子公司少數股東權益暨關聯交易的議案》,董事會同意公司以自有資金人民幣396.4萬元收購關聯人朱瀟挺所持芯儀微20%少數股東權益,本次交易完成後,公司持有芯儀微100%股權,芯儀微成為公司的全資子公司。
截至本公吿披露日,公司已根據《股權轉讓協議》的約定向交易對方支付了全部股權轉讓價款合計396.4萬元。芯儀微已於近日完成了上述股權轉讓事宜相關的工商變更登記手續,並取得了由蘇州工業園區市場監督管理局換髮的《營業執照》。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.